Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug in ATTR Amyloidosis with Cardiomyopathy
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 , an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
NevGold Announces Up To 53.7% Antimony, And Fourteen Samples Over 2% Antimony, From Surface Sampling On Pre-Strip Dump
TomaGold Completes Extension Drilling Program at Berrigan Mine and Launches Major Prospecting and Geophysical Survey Campaign Across its Chibougamau Properties
